# Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors

> **NCT00253565** · PHASE1 · COMPLETED · sponsor: **Herbert Hurwitz** · enrollment: 25 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** capecitabine
- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00253565
- **Lead sponsor:** Herbert Hurwitz
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2006-07
- **Final completion:** 2010-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00253565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00253565, "Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00253565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*